CN100402580C - 经修饰的生物相关物质、其制备方法、及中间体 - Google Patents

经修饰的生物相关物质、其制备方法、及中间体 Download PDF

Info

Publication number
CN100402580C
CN100402580C CNB2003801037963A CN200380103796A CN100402580C CN 100402580 C CN100402580 C CN 100402580C CN B2003801037963 A CNB2003801037963 A CN B2003801037963A CN 200380103796 A CN200380103796 A CN 200380103796A CN 100402580 C CN100402580 C CN 100402580C
Authority
CN
China
Prior art keywords
compound
group
formula
chemical formula
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2003801037963A
Other languages
English (en)
Chinese (zh)
Other versions
CN1714116A (zh
Inventor
中本宪一郎
大桥俊辅
山本裕二
坂上研二
伊藤智佳
安河内徹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOF Corp
Original Assignee
NOF Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOF Corp filed Critical NOF Corp
Publication of CN1714116A publication Critical patent/CN1714116A/zh
Application granted granted Critical
Publication of CN100402580C publication Critical patent/CN100402580C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polyethers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CNB2003801037963A 2002-11-20 2003-11-20 经修饰的生物相关物质、其制备方法、及中间体 Expired - Lifetime CN100402580C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP337113/2002 2002-11-20
JP2002337113 2002-11-20

Publications (2)

Publication Number Publication Date
CN1714116A CN1714116A (zh) 2005-12-28
CN100402580C true CN100402580C (zh) 2008-07-16

Family

ID=32321831

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801037963A Expired - Lifetime CN100402580C (zh) 2002-11-20 2003-11-20 经修饰的生物相关物质、其制备方法、及中间体

Country Status (11)

Country Link
US (4) US20050058620A1 (enExample)
EP (3) EP1911788B1 (enExample)
JP (2) JP4412461B2 (enExample)
KR (1) KR100988733B1 (enExample)
CN (1) CN100402580C (enExample)
AT (1) ATE388186T1 (enExample)
AU (1) AU2003302031A1 (enExample)
CA (1) CA2502948C (enExample)
DE (1) DE60319568T2 (enExample)
IL (2) IL168238A (enExample)
WO (1) WO2004046222A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US8003117B2 (en) * 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
US8828373B2 (en) * 2002-11-20 2014-09-09 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
RS20050501A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7932364B2 (en) 2003-05-09 2011-04-26 Novo Nordisk A/S Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
JP4877225B2 (ja) * 2005-02-18 2012-02-15 日油株式会社 ポリオキシアルキレン誘導体
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1787660A1 (en) * 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
JP2009536963A (ja) * 2006-05-12 2009-10-22 ドン・ア・ファーム・カンパニー・リミテッド ポリエチレングリコール−インターフェロンα結合体
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
JP5277599B2 (ja) * 2006-09-29 2013-08-28 日油株式会社 生分解性ポリオキシアルキレン誘導体の製造方法
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008060780A2 (en) * 2006-10-04 2008-05-22 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
JP5515224B2 (ja) 2007-02-28 2014-06-11 日油株式会社 多分岐鎖ポリオキシアルキレン誘導体
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
US20090246430A1 (en) 2008-03-28 2009-10-01 The Coca-Cola Company Bio-based polyethylene terephthalate polymer and method of making same
CN105254858A (zh) 2009-03-03 2016-01-20 可口可乐公司 生物基聚对苯二甲酸乙二酯包装及制备其的方法
JP5418360B2 (ja) * 2009-03-27 2014-02-19 日油株式会社 ポリオキシアルキレン誘導体の製造方法
JP5589503B2 (ja) * 2009-03-31 2014-09-17 日油株式会社 多分岐鎖ポリオキシアルキレン化合物、その製造方法および中間体
JP5569787B2 (ja) * 2009-03-31 2014-08-13 日油株式会社 高分子量ポリエチレングリコール化合物の精製方法
US8816099B2 (en) * 2010-03-31 2014-08-26 Nof Corporation Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
US10040761B2 (en) 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
CA2803446C (en) 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
JP5949037B2 (ja) 2011-03-30 2016-07-06 日油株式会社 末端に複数の水酸基を有するポリオキシエチレン誘導体
WO2014157150A1 (ja) 2013-03-25 2014-10-02 日油株式会社 ベンジリデンアセタールリンカーを有する親水性ポリマー誘導体
EP2980115B1 (en) 2013-03-27 2019-03-06 NOF Corporation Purification method for polyethylene glycol having a single amino group
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
CN103881084B (zh) * 2014-03-14 2016-09-28 厦门赛诺邦格生物科技股份有限公司 一种支化聚乙二醇的磷脂类衍生物及其组成的脂质膜结构体
WO2017043653A1 (ja) * 2015-09-11 2017-03-16 国立大学法人 東京大学 タンパク質を安定化するための化合物
JP6860827B2 (ja) * 2016-04-28 2021-04-21 日油株式会社 分岐型ポリオキシエチレン化合物およびコンタクトレンズ
US11613607B2 (en) 2016-10-07 2023-03-28 Tokyo Institute Of Technology Branched type hetero monodispersed polyethylene glycol, production method thereof, and conjugate thereof
JP6935059B2 (ja) 2017-03-30 2021-09-15 日油株式会社 カルボキシル基を一つ有するポリエチレングリコールの精製方法
CA3094055A1 (en) 2018-03-20 2019-09-26 Nof Corporation Branched monodispersed polyethylene glycol, intermediate and methods for producing same
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
CA3164940A1 (en) 2019-12-27 2021-07-01 Nof Corporation Method for purifying branched polyethylene glycol
KR102860222B1 (ko) 2019-12-27 2025-09-16 니치유 가부시키가이샤 폴리에틸렌 글리콜 화합물의 정제 방법
US20250197564A1 (en) 2022-03-09 2025-06-19 Nof Corporation Method for producing polyoxyethylene derivative, method for quantitating polyoxyethylene compound, and labeling reagent for analysis use
US20250179245A1 (en) * 2022-03-17 2025-06-05 Nof Corporation Method for producing polyethylene glycol derivative
EP4786520A1 (en) 2023-09-27 2026-08-05 NOF Corporation Method for producing polyethylene glycol derivative having carboxyl group at terminal
WO2025070456A1 (ja) 2023-09-29 2025-04-03 日油株式会社 高純度の分岐鎖状ポリエチレングリコール化合物の製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0859818A (ja) * 1994-08-23 1996-03-05 Nippon Oil & Fats Co Ltd グリセリンポリアルキレングリコールエーテル誘導体
JPH11228685A (ja) * 1998-02-12 1999-08-24 Nof Corp カルボキシル基含有ポリオキシアルキレン化合物
JP2000001541A (ja) * 1998-06-15 2000-01-07 Nof Corp アミノ基含有ポリオキシアルキレン化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3025807A1 (de) * 1980-07-08 1982-02-04 Th. Goldschmidt Ag, 4300 Essen Verfahren zur herstellung von polyaethern unter erhalt von mindestens zwei freien hydroxylgruppen am startalkohol
JPH02242823A (ja) * 1989-03-02 1990-09-27 Kiyouseki Seihin Gijutsu Kenkyusho:Kk シアノエチル化ポリエーテルポリオール及び該化合物を有効成分として含有する冷凍機油
US5118448A (en) * 1990-10-19 1992-06-02 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated polyols
JP3218755B2 (ja) * 1992-11-12 2001-10-15 日本油脂株式会社 グリセリンエーテルエステル
JP2000230000A (ja) * 1999-02-08 2000-08-22 Hokkaido Univ 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体
JP4123856B2 (ja) * 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0859818A (ja) * 1994-08-23 1996-03-05 Nippon Oil & Fats Co Ltd グリセリンポリアルキレングリコールエーテル誘導体
JPH11228685A (ja) * 1998-02-12 1999-08-24 Nof Corp カルボキシル基含有ポリオキシアルキレン化合物
JP2000001541A (ja) * 1998-06-15 2000-01-07 Nof Corp アミノ基含有ポリオキシアルキレン化合物

Also Published As

Publication number Publication date
KR100988733B1 (ko) 2010-10-20
JP4412461B2 (ja) 2010-02-10
EP1564236A4 (en) 2006-01-25
DE60319568D1 (de) 2008-04-17
US20050058620A1 (en) 2005-03-17
IL194501A (en) 2011-11-30
CA2502948C (en) 2013-04-02
EP1564236A1 (en) 2005-08-17
AU2003302031A1 (en) 2004-06-15
EP1911789B1 (en) 2016-04-27
JP5273589B2 (ja) 2013-08-28
JP2009102649A (ja) 2009-05-14
DE60319568T2 (de) 2009-04-02
US20050288490A1 (en) 2005-12-29
EP1911788B1 (en) 2019-03-27
US7524875B2 (en) 2009-04-28
JP2004197077A (ja) 2004-07-15
EP1911788A1 (en) 2008-04-16
KR20050083923A (ko) 2005-08-26
US20090192320A1 (en) 2009-07-30
EP1564236B1 (en) 2008-03-05
EP1911789A1 (en) 2008-04-16
CN1714116A (zh) 2005-12-28
US8034981B2 (en) 2011-10-11
US20110082277A1 (en) 2011-04-07
CA2502948A1 (en) 2004-06-03
WO2004046222A1 (ja) 2004-06-03
IL168238A (en) 2009-09-22
US7851491B2 (en) 2010-12-14
ATE388186T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
KR100988733B1 (ko) 개질된 생체 관련 물질, 이의 제조방법 및 중간체
EP1283233B1 (en) Polyoxyalkylene derivative and process of producing the same
JP4490290B2 (ja) 加水分解安定性マレイミド末端ポリマー
CN101622295B (zh) 多支链聚氧化亚烷基衍生物
JP3310000B2 (ja) 水溶性高分子抗癌剤及び薬物担持用担体
JP2017119706A (ja) 多分岐ポリマーのプロドラッグ
JP7042053B2 (ja) 分岐型ヘテロ単分散ポリエチレングリコール、その製造方法、及びその結合体
CN102985462A (zh) 支链异聚乙二醇和中间体
US8003117B2 (en) Polyalkylene glycol derivative and modified bio-related substance
JP5017107B2 (ja) ポリペプチド等と反応し得る官能基を含むリビングラジカル重合開始剤、それを用いて得られる櫛形ポリマー、それから得られるポリペプチド複合体及び薬剤
JPH06206830A (ja) ブロック共重合体−薬剤複合体及び高分子ブロック共重合体
KR100480423B1 (ko) 에리트로포이에틴과 폴리에틸렌글리콜 유도체의 배합체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20080716

CX01 Expiry of patent term